Hypertrophic cardiomyopathy: a modern view of the problem
- Authors: Kalyagin A.N.1,2, Gamayunov D.Y.1, Silkin V.I.2, Kurkov N.N.2
-
Affiliations:
- Irkutsk State Medical University
- Irkutsk City Clinical Hospital No.1
- Issue: Vol 104, No 4 (2023)
- Pages: 541-551
- Section: Reviews
- URL: https://bakhtiniada.ru/kazanmedj/article/view/145715
- DOI: https://doi.org/10.17816/KMJ110938
- ID: 145715
Cite item
Abstract
Cardiomyopathy is considered one of the main causes of heart failure and sudden cardiac death, at least in young people. Approximately 50% of patients who die suddenly in childhood or adolescence or undergo heart transplantation suffer from this condition. The purpose of this literature review is to study and highlight the issues of etiology, pathogenesis, clinical features, diagnosis and treatment of hypertrophic cardiomyopathy from the point of view of modern ideas. The search and analysis of domestic and foreign literature materials using the PubMed and eLibrary databases was carried out. Of particular interest is the etiology of primary congenital cardiomyopathies, in respect of which research continues. As a result of the implementation of genetic factors, multiple structural and functional changes in the myocardium develop, which lead to changes in hemodynamics. Cardiomyopathy is a clinically heterogeneous disease, and one of the factors that determine the clinical phenotype is the genotype. In addition to standard laboratory testing, patients with suspected hypertrophic cardiomyopathy are advised to undergo medical genetic counseling to identify the causative mutation, and often to obtain prognostic information. The fundamental imaging method is echocardiography, but the role of magnetic resonance imaging in the diagnosis of the disease is also considered. Patients with symptomatic obstructive hypertrophic cardiomyopathy are usually recommended first-line pharmacotherapy with β-blockers or non-dihydropyridine calcium channel blockers. Currently, research on new drugs for the treatment of hypertrophic cardiomyopathy — inhibitors of cardiac myosin is ongoing. Surgical methods of treatment are developing progressively, however, methods of conservative treatment require further active research of drugs that have not been used before.
Full Text
##article.viewOnOriginalSite##About the authors
Alexey N. Kalyagin
Irkutsk State Medical University; Irkutsk City Clinical Hospital No.1
Author for correspondence.
Email: akalagin@mail.ru
ORCID iD: 0000-0002-2708-3972
SPIN-code: 6737-0285
M.D., D. Sci. (Med.), Prof., Vice-rector for Medical Work and Postgraduate Education, Head of Depart., Depart. of Propedeutics of Internal Diseases
Russian Federation, Irkutsk, Russia; Irkutsk, RussiaDanil Yu. Gamayunov
Irkutsk State Medical University
Email: d.gamayunov@mail.ru
ORCID iD: 0000-0001-9348-9025
SPIN-code: 7222-6890
M.D., Resident, Depart. of Propedeutics of Internal Diseases
Russian Federation, Irkutsk, RussiaViktor I. Silkin
Irkutsk City Clinical Hospital No.1
Email: silkin1957@inbox.ru
M.D., Anesthesiologist-Resuscitator
Russian Federation, Irkutsk, RussiaNikolay N. Kurkov
Irkutsk City Clinical Hospital No.1
Email: kurkov.nn@yandex.ru
ORCID iD: 0000-0002-6397-1731
SPIN-code: 1859-1378
M.D., Anesthesiologist-Resuscitator
Russian Federation, Irkutsk, RussiaReferences
- Lannou S, Mansencal N, Couchoud C, Lassalle M, Dubourg O, Stengel B, Jacquelinet C, Charron P. The public health burden of cardiomyopathies: Insights from a Nationwide Inpatient Study. J Clin Med. 2020; 9(4):920. doi: 10.3390/jcm9040920.
- Seferović PM, Polovina M, Bauersachs J, Arad M, Gal TB, Lund LH, Felix SB, Arbustini E, Caforio ALP, Farmakis D, Filippatos GS, Gialafos E, Kanjuh V, Krljanac G, Limongelli G, Linhart A, Lyon AR, Maksimović R, Miličić D, Milinković I, Noutsias M, Oto A, Oto Ö, Pavlović SU, Piepoli MF, Ristić AD, Rosano GMC, Seggewiss H, Ašanin M, Seferović JP, Ruschitzka F, Čelutkiene J, Jaarsma T, Mueller C, Moura B, Hill L, Volterrani M, Lopatin Y, Metra M, Backs J, Mullens W, Chioncel O, de Boer RA, Anker S, Rapezzi C, Coats AJS, Tschöpe C. Heart failure in cardiomyopathies: A position paper from the Heart Fai-lure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(5):553–576. doi: 10.1002/ejhf.1461.
- National clinical guideline on diagnosis and treatment of hypertrophic cardiomyopathy. Russian cardiology bulletin. 2016;11(1):3–22. (In Russ.)
- Vnutrennie bolezni. Serdechno-sosudistaya sistema. (Internal diseases. Cardiovascular system.) Tutorial. GE Roytberg, AV Strutynskiy, editors. 6nd ed. M.: MEDpress-inform; 2019. 904 р. (In Russ.)
- Martinez HR, Beasley GS, Miller N, Goldberg JF, Jefferies JL. Clinical insights into heritable cardiomyopathies. Front Genet. 2021;12:663450. doi: 10.3389/fgene.2021.663450.
- Stolfo D, Collini V, Sinagra G. Advanced heart failure in special population: Cardiomyopathies and myocarditis. Heart Fail Clin. 2021;17(4):661–672. doi: 10.1016/j.hfc.2021.05.010.
- McKenna WJ, Maron BJ, Thiene G. Classification, epidemiology, and global burden of cardiomyopathies. Circ Res. 2017;121(7):722–730. doi: 10.1161/CIRCRESAHA.117.309711.
- Sinagra G, Carriere C, Clemenza F, Minà C, Bandera F, Zaffalon D, Gugliandolo P, Merlo M, Guazzi M, Agostoni P. Risk stratification in cardiomyo-pathy. Eur J Prev Cardiol. 2020;27(2):52–58. doi: 10.1177/2047487320961898.
- Kochergin-Nikitsky KS, Zaklyazminskaya EV, Lavrov AV, Smirnikhina SA. Cardiomyopathies associated with the DES gene mutations: molecular pathogenesis and gene therapy approaches. Almanac of Clinical Medicine. 2019;47(7):603–613. (In Russ.) doi: 10.18786/2072-0505-2019-47-025.
- Yamada T, Nomura S. Recent findings related to cardiomyopathy and genetics. Int J Mol Sci. 2021;22(22):12522. doi: 10.3390/ijms222212522.
- Bonaventura J, Polakova E, Vejtasova V, Veselka J. Genetic testing in patients with hypertrophic cardiomyopathy. Int J Mol Sci. 2021;22(19):10401. doi: 10.3390/ijms221910401.
- Sabater-Molina M, Perez-Sanchez I, Hernandez Del Rincon JP, Gimeno JR. Genetics of hypertrophic cardiomyopathy: A review of current state. Clin Genet. 2018;93(1):3–14. doi: 10.1111/cge.13027.
- Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Rowin EJ, Maron MS, Sherrid MV. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79(4):372–389. doi: 10.1016/j.jacc.2021.12.002.
- De Oliveira GMM. A new look into hypertrophic cardiomyopathy based on clinical evidence. Rev Port Cardiol (Engl Ed). 2018;37(1):11–13. doi: 10.1016/j.repc.2018.01.001.
- Chou C, Chin MT. Pathogenic mechanisms of hypertrophic cardiomyopathy beyond sarcomere dysfunction. Int J Mol Sci. 2021;22(16):8933. doi: 10.3390/ijms22168933.
- Lioncinо M, Monda E, Verrillo F, Moscarella E, Calcagni G, Drago F, Marino B, Digilio MC, Putotto C, Calabrò P, Russo MG, Roberts AE, Gelb BD, Tartaglia M, Limongelli G. Hypertrophic cardiomyopathy in RASopathies: Diagnosis, clinical characteristics, prognostic implications, and management. Heart Fail Clin. 2022;18(1):19–29. doi: 10.1016/j.hfc.2021.07.004.
- Tadros R, Francis C, Xu X, Vermeer AMC, Harper AR, Huurman R, Kelu Bisabu K, Walsh R, Hoorntje ET, Te Rijdt WP, Buchan RJ, van Velzen HG, van Slegtenhorst MA, Vermeulen JM, Offerhaus JA, Bai W, de Marvao A, Lahrouchi N, Beekman L, Karper JC, Veldink JH, Kayvanpour E, Pantazis A, Baksi AJ, Whiffin N, Mazzarotto F, Sloane G, Suzuki H, Schneider-Luftman D, Elliott P, Richard P, Ader F, Villard E, Lichtner P, Meitinger T, Tanck MWT, van Tintelen JP, Thain A, McCarty D, Hegele RA, Roberts JD, Amyot J, Dubé MP, Cadrin-Tourigny J, Giraldeau G, L’Allier PL, Garceau P, Tardif JC, Boekholdt SM, Lumbers RT, Asselbergs FW, Barton PJR, Cook SA, Prasad SK, O’Regan DP, van der Velden J, Verweij KJH, Talajic M, Lettre G, Pinto YM, Meder B, Charron P, de Boer RA, Christiaans I, Michels M, Wilde AAM, Watkins H, Matthews PM, Ware JS, Bezzina CR. Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nat Genet. 2021;53(2):128–134. doi: 10.1038/s41588-020-00762-2.
- Santini L, Coppini R, Cerbai E. Ion channel impairment and myofilament Ca2+ sensitization: Two parallel mechanisms underlying arrhythmogenesis in hypertrophic cardiomyopathy. Cells. 2021;10(10):2789. doi: 10.3390/cells10102789.
- Ranjbarvaziri S, Kooiker KB, Ellenberger M, Fajardo G, Zhao M, Roest ASV, Woldeyes RA, Koyano TT, Fong R, Ma N, Tian L, Traber GM, Chan F, Perrino J, Reddy S, Chiu W, Wu JC, Woo JY, Ruppel KM, Spudich JA, Snyder MP, Contrepois K, Bernstein D. Altered cardiac energetics and mitochondrial dysfunction in hypertrophic cardiomyopathy. Circulation. 2021;144(21):1714–1731. doi: 10.1161/CIRCULATIONAHA.121.053575.
- Lee DZJ, Rakowski H. Hypertrophic cardiomyopathy in elderly individuals: Is it a rose by another name? J Am Heart Assoc. 2021;10(3):e020204. doi: 10.1161/JAHA.120.020204.
- Muresan ID, Agoston-Coldea L. Phenotypes of hypertrophic cardiomyopathy: Genetics, clinics, and modular imaging. Heart Fail Rev. 2021;26(5):1023–1036. doi: 10.1007/s10741-020-09931-1.
- Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Cirino AL, Fox JC, Lakdawala NK, Ware JS, Caleshu CA, Helms AS, Colan SD, Girolami F, -Cecchi F, Seidman CE, Sajeev G, Signorovitch J, Green EM, Olivotto I. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: Insights from the sarcomeric human cardiomyopathy registry (SHaRe). Circulation. 2018;138(14):1387–1398. doi: 10.1161/CIRCULATIONAHA.117.033200.
- Borsari W, Davis L, Meiers E, Salberg L, McDonough B. Living with hypertrophic cardiomyopathy: A patient’s perspective. Future Cardiol. 2022;18(1):43–50. doi: 10.2217/fca-2021-0091.
- Balla EA, Taub GS. Hypertrophic cardiomyopathy: curreut issues and problems. Lechebnoe delo: nauchno-prakticheskiy terapevticheskiy zhurnal. 2017;(1):52–56. (In Russ.)
- Teekakirikul P, Zhu W, Huang HC, Fung E. Hypertrophic cardiomyopathy: An overview of genetics and management. Biomolecules. 2019;9(12):878. doi: 10.3390/biom9120878.
- Gabrusenko SA, Gudkova AY, Koziolova NA, Alexandrova SA, Berseneva MI, Gordeev ML, Dzemeshkevich SL, Zaklyazminskaya EV, Irtyuga OB, Kaplunova VYu, Kostareva AA, Krutikov AN, Malenkov DA, Novikova TN, Saidova MA, Sanakoev MK, Stukalova OV. 2020 Clinical practice guidelines for hypertrophic cardiomyopathy. Russian Journal of Cardiology. 2021;26(5):269–334. (In Russ.) doi: 10.15829/1560-4071-2021-4541.
- Ciarambino T, Menna G, Sansone G, Giordano M. Cardiomyopathies: An overview. Int J Mol Sci. 2021;22(14):7722. doi: 10.3390/ijms22147722.
- Maurizi N, Michels M, Rowin EJ, Semsarian C, Girolami F, Tomberli B, Cecchi F, Maron MS, Olivotto I, Maron BJ. Clinical course and significance of hypertrophic cardiomyopathy without left ventricular hypertrophy. Circulation. 2019;139(6):830–833. doi: 10.1161/CIRCULATIONAHA.118.037264.
- Haland TF, Edvardsen T. The role of echocardiography in management of hypertrophic cardiomyopathy. J Echocardiogr. 2020;18(2):77–85. doi: 10.1007/s12574-019-00454-9.
- Gazun LO, Polukhina EV. Some aspects of cardiomyopathy ultrasonic diagnosis. Public health of the Far East. 2017;(4):75–79. (In Russ.)
- Konstant Dzh. Klini-cheskaya diagnostika zabolevaniy serdtsa (kardiolog u posteli bol’nogo). (Clinical diagnosis of heart diseases (cardiologist at the patient’s bedside).) Translation from English. M.: BINOM; 2017. 448 р. (In Russ.)
- Karaca Özer P, Ayduk Gövdeli E, Engin B, Atıcı A, Baykız D, Orta H, Demirtakan ZG, Emet S, Elitok A, Tayyareci Y, Umman B, Bilge AK, Buğra Z. Role of global longitudinal strain in discriminating variant forms of left ventricular hypertrophy and predicting mortality. The Anatol J Cardiol. 2021;25(12):863–871. doi: 10.5152/AnatolJCardiol.2021.21940.
- Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17:1321–1360. doi: 10.1093/ehjci/jew082.
- Gluckman TJ. Hypertrophic cardiomyopathy: Diagnosis and therapeutic options. Am J Manag Care. 2021;27(6):S111–S117. doi: 10.37765/ajmc.2021.88628.
- Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB. Hypertrophic cardiomyopathy: The future of treatment. Eur J Heart Fail. 2020;22(2):228–240. doi: 10.1002/ejhf.1715.
- Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Dearani JA, Rowin EJ, Maron MS, Sherrid MV. Management of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79(4):390–414. doi: 10.1016/j.jacc.2021.11.021.
- Dybro AM, Rasmussen TB, Nielsen RR, Andersen MJ, Jensen MK, Poulsen SH. Randomized trial of Metoprolol in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2021;78(25):2505–2517. doi: 10.1016/j.jacc.2021.07.065.
- Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A, Kubanek M, Wojakowski W, Jensen MK, Gimeno-Blanes J, Afshar K, Myers J, Hegde SM, Solomon SD, Sehnert AJ, Zhang D, Li W, Bhattacharya M, Edelberg JM, Waldman CB, Lester SJ, Wang A, Ho CY, Jacoby D; EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759–769. doi: 10.1016/S0140-6736(20)31792-X.
- Zampieri M, Berteotti M, Ferrantini C, Tassetti L, Gabriele M, Tomberli B, Castelli G, Cappelli F, Stefàno P, Marchionni N, Coppini R, Olivotto I. Pathophysiology and treatment of hypertrophic cardiomyopathy: New perspectives. Curr Heart Fail Rep. 2021;18(4):169–179. doi: 10.1007/s11897-021-00523-0.
- Goldspink PH, Warren CM, Kitajewski J, Wolska BM, Solaro RJ. A perspective on personalized therapies in hypertrophic cardiomyopathy. J Cardiovasc Pharmacol. 2021;77(3):317–322. doi: 10.1097/FJC.0000000000000968.
- Taddei-Allen P. Hypertrophic cardiomyopathy considerations for the managed care pharmacist. Am J Manag Care. 2021;27(6):S118–S125. doi: 10.37765/ajmc.2021.88629.
- Maron MS, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A, Garcia-Pavia P, Lakdawala NK, Nagueh SF, Rader F, Tower-Rader A, Turer AT, Coats C, Fifer MA, Owens A, Solomon SD, Watkins H, Barriales-Villa R, Kramer CM, Wong TC, Paige SL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham T; REDWOOD-HCM Steering Committee and Investigators. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023;81(1):34–45. doi: 10.1016/j.jacc.2022.10.020.
- Ferrantini C, Pioner JM, Mazzoni L, Gentile F, Tosi B, Rossi A, Belardinelli L, Tesi C, Palandri C, Matucci R, Cerbai E, Olivotto I, Poggesi C, Mugelli A, Coppini R. Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: An in vitro study in human myocardium. Br J Pharmacol. 2018;175(13):2635–2652. doi: 10.1111/bph.14223.
- Jiang Z, Tang M, Liu H, Ma N, Ding F, Bao C, Mei J. Minimally invasive surgery for hypertrophic obstructive cardiomyopathy with mitral regurgitation. Ann Thorac Surg. 2021;111(4):1345–1350. doi: 10.1016/j.athoracsur.2020.06.028.
- Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Nishimura RA, Ralph-Edwards A, Rakowski H, Sherrid MV, Swistel DG, Balaram S, Rastegar H, Rowin EJ, Smedira NG, Lytle BW, Desai MY, Lever HM. Low operative mortality achieved with surgical septal myectomy: Role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction. J Am Coll Cardiol. 2015;66(11):1307–1308. doi: 10.1016/j.jacc.2015.06.1333.
- Rowin EJ, Maron BJ, Romashko M, Wang W, Rastegar H, Link MS, Maron MS. Impact of effective management strategies on patients with the most extreme phenotypic expression of hypertrophic cardiomyopathy. Am J Cardiol. 2019;124(1):113–121. doi: 10.1016/j.amjcard.2019.04.002.
- Nguyen A, Schaff HV, Nishimura RA, Geske JB, Dearani JA, King KS, Ommen SR. Apical myectomy for patients with hypertrophic cardiomyopathy and advanced heart failure. J Thorac Cardiovasc Surg. 2019;S0022–5223(19)30772-X. doi: 10.1016/j.jtcvs.2019.03.088.
- Rowin EJ, Maron BJ, Carrick RT, Patel PP, Koethe B, Wells S, Maron MS. Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systo-lic dysfunction. J Am Coll Cardiol. 2020;75(24):3033–3043. doi: 10.1016/j.jacc.2020.04.045.
Supplementary files
